Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29705231 | 1.00 | NPSR1 (0.56) | NPSR1TDP1POLBMEN1KMT2A | |
| SCHEMBL11024360 | 0.84 | NPSR1 (0.48) | NPSR1TDP1POLBMEN1KMT2A | |
| SCHEMBL11023076 | 0.84 | NPSR1 (0.48) | NPSR1TDP1POLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL9091123 | 0.84 | NPSR1 (0.71) | NPSR1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL6111796 | 0.82 | NPSR1 (0.50) | NPSR1TDP1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4337042 | 0.82 | NPSR1 (0.50) | NPSR1TDP1POLBMEN1KMT2A | |
| SCHEMBL1614180 | 0.82 | TDP1 (0.63) | NPSR1TDP1POLBMEN1KMT2A | |
| SCHEMBL29512558 | 0.82 | TDP1 (0.63) | NPSR1TDP1POLBMEN1KMT2A | |
| SCHEMBL117827 | 0.81 | NPSR1 (0.54) | NPSR1TDP1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29502585 | 0.81 | NPSR1 (0.54) | NPSR1TDP1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114702440-B | Preparation method of picloram and picloram prepared by same | 永农生物科学有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-114702440-A | Preparation method of picloram and picloram prepared by same | 永农生物科学有限公司 | 2022-07-05 | — | — | CN | disclosed |
| EP-3297436-A1 | RECOVERY AND/OR REUSE OF PALLADIUM CATALYST AFTER A SUZUKI COUPLING | Dow AgroSciences LLC (US) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016191245-A1 | RECOVERY AND/OR REUSE OF PALLADIUM CATALYST AFTER A SUZUKI COUPLING | DOW AGROSCIENCES LLC (US) | 2016-12-01 | — | — | WO | disclosed |
| US-20160340311-A1 | RECOVERY AND/OR REUSE OF PALLADIUM CATALYST AFTER A SUZUKI COUPLING | DOW AGROSCIENCES LLC (US) | 2016-11-24 | — | — | US | disclosed |
| US-8063049-B2 | Inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063049-B2 | Inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100331334-A1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331334-A1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. | 2010-12-30 | — | — | US | disclosed |
| US-7820664-B2 | Inhibitors of MEK | BAYER SCHERING PHARMA AG (DE) | 2010-10-26 | — | — | US | disclosed |
| US-7820664-B2 | Inhibitors of MEK | BAYER SCHERING PHARMA AG (DE) | 2010-10-26 | — | — | US | disclosed |
| US-7576072-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | ARDEA BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | ARDEA BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1689406-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1689406-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050153942-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005051906-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | MAPK8, MAP3K8, MAP3K2 | NPSR1 3857/4885TDP1 1113/4885POLB 1544/4885 |
| US-20100331334-A1 | INHIBITORS OF MEK | NRAS, BRAF, KSR2 | NPSR1 4661/4885TDP1 810/4885POLB 934/4885 |
| US-20160340311-A1 | RECOVERY AND/OR REUSE OF PALLADIUM CATALYST AFTER A SUZUKI COUPLING | DDT, PARK7, DDO | NPSR1 3139/4885TDP1 299/4885POLB 71/4885 |
| US-20050153942-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | NPSR1 3090/4885TDP1 1057/4885POLB 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.